Gestational trophoblastic diseases: new standards for therapy

Area of Science:

• Gynecology
• Oncology
• Genetics

Background:

• Gestational trophoblastic disease (GTD) represents a group of rare neoplastic disorders.
• GTD ranges from partial hydatidiform mole to choriocarcinoma, with varying metastatic potential and treatment needs.
• Despite advancements, the incidence of persistent GTD has not declined.

Purpose of the Study:

• To review recent advancements in the epidemiology, genetics, diagnosis, and treatment of GTD.
• To highlight the evolving understanding of these rare neoplastic conditions.

Main Methods:

• Literature review of recent studies on GTD.
• Analysis of epidemiological data and genetic research.
• Evaluation of diagnostic technologies like ultrasonography and beta-human chorionic gonadotropin testing.

Main Results:

• Significant progress has been made in understanding GTD epidemiology and genetics.
• Technological advancements have altered the presentation of molar pregnancy.
• Multi-agent chemotherapy remains the standard for choriocarcinoma.

Conclusions:

• GTD is a highly curable spectrum of diseases, even with metastasis.
• Continued research in genetics and diagnostics is crucial for improving patient outcomes.
• Early detection and tailored treatment strategies are key for managing GTD effectively.